"These results are extraordinary for a single agent treating these chemotherapy-resistant tumors," the study's principal investigator Sant Chawla of the Sarcoma Oncology Center in Santa Monica said in a statement. "Aldoxorubicin is the first and only single agent to surpass doxorubicin as a first-line treatment for soft tissue sarcomas."
In other CytRx news, major shareholder Scott Bradford Patterson purchased 284,979 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average price of $2.44 per share, with a total value of $695,348.76. Following the completion of the transaction, the insider now directly owns 4,912,584 shares of the company’s stock, valued at approximately $11,986,705. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
100% superiority over doxorubicin.
partnership, buyout, or accelerated approval to be announced soon.
aldoxorubicin will be a blockbuster
THIS IS A BLOCKBUSTER
AND I MEAN MEGA GAPPPPPPPPPPPPPP